Levin Capital Strategies’s Standard BioTools LAB Stock Holding History

Levin Capital Strategies’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,672	Closed	-$26.7K	–	291
2023 Q1	$26.7K	Hold	13,672	–	–	﹤0.01%	233
2022 Q4	$16K	Hold	13,672	–	–	﹤0.01%	235
2022 Q3	$15K	Hold	13,672	–	–	﹤0.01%	229
2022 Q2	$22K	Hold	13,672	–	–	﹤0.01%	257
2022 Q1	$49K	Hold	13,672	–	–	﹤0.01%	299
2021 Q4	$54K	Hold	13,672	–	–	0.01%	319
2021 Q3	$90K	Hold	13,672	–	–	0.01%	324
2021 Q2	$84K	Hold	13,672	–	–	0.01%	348
2021 Q1	$62K	Sell	13,672 -28,687	-68%	-$158K	0.01%	329
2020 Q4	$254K	Sell	42,359 -16,383	-28%	-$108K	0.03%	226
2020 Q3	$436K	Sell	58,742 -130,724	-69%	-$902K	0.06%	147
2020 Q2	$760K	Buy	189,466 +26,878	+17%	+$93.6K	0.1%	89
2020 Q1	$413K	Buy	162,588 +21,000	+15%	+$69K	0.07%	96
2019 Q4	$493K	Sell	141,588 -11,841	-8%	-$41.7K	0.05%	116
2019 Q3	$710K	Sell	153,429 -21,000	-12%	-$165K	0.08%	101
2019 Q2	$2.15M	Sell	174,429 -6,427	-4%	-$81.9K	0.21%	66
2019 Q1	$2.4M	Sell	180,856 -9,386,212	-98%	-$98.9M	0.27%	55
2018 Q4	$82.5M	Sell	9,567,068 -634,723	-6%	-$4.94M	1.82%	21
2018 Q3	$76.4M	Sell	10,201,791 -6,531	-0.1%	-$46.4K	1.31%	24
2018 Q2	$60.8M	Buy	10,208,322 +492,914	+5%	+$2.81M	1.05%	30
2018 Q1	$56.7M	Buy	9,715,408 +548,338	+6%	+$3.6M	1.03%	30
2017 Q4	$54M	Buy	9,167,070 +463,310	+5%	+$2.54M	0.91%	33
2017 Q3	$43.9M	Buy	8,703,760 +2,948,007	+51%	+$12.4M	0.74%	34
2017 Q2	$23.3M	Hold	5,755,753	–	–	0.41%	43
2017 Q1	$32.8M	Hold	5,755,753	–	–	0.58%	40
2016 Q4	$41.9M	Buy	5,755,753 +1,370,490	+31%	+$8.61M	0.72%	38
2016 Q3	$35.1M	Buy	4,385,263 +789,688	+22%	+$7.25M	0.52%	40
2016 Q2	$32.5M	Buy	3,595,575 +1,505,320	+72%	+$14.1M	0.59%	40
2016 Q1	$16.9M	Buy	+2,090,255	New	+$15.1M	0.31%	57

Other funds holding LAB

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Levin Capital Strategies's LAB Position: Q2 2023 in Review

Levin Capital Strategies sold out of Standard BioTools (LAB) in Q2 2023, closing a stake of 13,672 shares — an estimated $26.7K sold.

Levin Capital Strategies first reported a position in LAB in Q1 2016 and held it in 29 quarters. The position peaked at $82.5M in Q4 2018. 66 funds tracked by Wall St. Rank hold LAB as of Q2 2023.

Levin Capital Strategies reported no remaining Standard BioTools position as of Q2 2023 after selling out during the quarter.
Levin Capital Strategies sold 13,672 Standard BioTools shares in Q2 2023, an estimated $26.7K.
Levin Capital Strategies first reported a position in Standard BioTools in Q1 2016 and held it in 29 quarters.
Levin Capital Strategies's Standard BioTools position peaked at $82.5M in Q4 2018.
66 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2023.

Based on Levin Capital Strategies's 13F filing for Q2 2023, filed 31 Jul 2023.